Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms.
作者信息
Tran Agnès, Bournerias François, Le Beller Christine, Mir Olivier, Rey Elisabeth, Pons Gérard, Delahousse Michel, Tréluyer Jean-Marc
出版信息
Br J Clin Pharmacol. 2008 Feb;65(2):279-80. doi: 10.1111/j.1365-2125.2007.03020.x. Epub 2007 Sep 13.
Abstract
摘要
相似文献
1
Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms.
Br J Clin Pharmacol. 2008 Feb;65(2):279-80. doi: 10.1111/j.1365-2125.2007.03020.x. Epub 2007 Sep 13.
2
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Pharmacogenet Genomics. 2008 Jun;18(6):515-23. doi: 10.1097/FPC.0b013e3282fc9766.
3
Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
Br J Clin Pharmacol. 2009 Jan;67(1):50-60. doi: 10.1111/j.1365-2125.2008.03321.x. Epub 2008 Nov 17.
4
Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer.
Clin Cancer Res. 2010 Dec 15;16(24):6169-76. doi: 10.1158/1078-0432.CCR-10-0281.
5
[Association between CYP2B6, CYP2D6, GSTP1 genetic polymorphisms and urinary styrene metabolites in professional workers].
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2009 Oct;27(10):589-92.
6
Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.
Fertil Steril. 2010 Jul;94(2):645-54. doi: 10.1016/j.fertnstert.2009.03.034. Epub 2009 Apr 18.
7
Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
Pharmacogenet Genomics. 2007 Jun;17(6):431-45. doi: 10.1097/FPC.0b013e328045c4fb.
8
Influence of genetic polymorphisms of styrene-metabolizing enzymes and smoking habits on levels of urinary metabolites after occupational exposure to styrene.
Toxicol Lett. 2005 Dec 30;160(1):84-91. doi: 10.1016/j.toxlet.2005.06.011. Epub 2005 Aug 25.
9
The importance of correct assignment of CYP2B6 genetic variants with respect to cyclophosphamide metabolizer status.
Am J Hematol. 2011 Apr;86(4):383-4; author reply 384. doi: 10.1002/ajh.21987.
10
Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance.
Clin Infect Dis. 2006 Feb 1;42(3):408-10. doi: 10.1086/499369. Epub 2005 Dec 27.
引用本文的文献
1
Influence of Genetic Variation of GST, CYP, and ABC on the Safety and Efficacy of Cyclophosphamide-Based Therapy.
Clin Transl Sci. 2025 Jul;18(7):e70301. doi: 10.1111/cts.70301.
2
Gene polymorphisms associated with immunosuppressant adverse effects in systemic lupus erythematosus: a narrative review.
Front Genet. 2025 Jun 24;16:1594648. doi: 10.3389/fgene.2025.1594648. eCollection 2025.
3
gene polymorphisms are associated with cyclophosphamide effectiveness in lupus nephritis patients: A case-control study in Indonesia.
Narra J. 2024 Dec;4(3):e1144. doi: 10.52225/narra.v4i3.1144. Epub 2024 Nov 15.
4
Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety.
Medicina (Kaunas). 2022 Dec 27;59(1):56. doi: 10.3390/medicina59010056.
5
Possible Susceptibility Genes for Intervention against Chemotherapy-Induced Cardiotoxicity.
Oxid Med Cell Longev. 2020 Oct 13;2020:4894625. doi: 10.1155/2020/4894625. eCollection 2020.
6
High-resolution melt analysis to detect sequence variations in highly homologous gene regions: application to CYP2B6.
Pharmacogenomics. 2013 Jun;14(8):913-22. doi: 10.2217/pgs.13.66.
7
Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.
Eur J Clin Pharmacol. 2012 Apr;68(4):389-95. doi: 10.1007/s00228-011-1134-0. Epub 2011 Oct 20.
本文引用的文献
1
Clinical pharmacokinetics of cyclophosphamide.
Clin Pharmacokinet. 2005;44(11):1135-64. doi: 10.2165/00003088-200544110-00003.
2
Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.
Eur J Pharm Sci. 2006 Jan;27(1):54-61. doi: 10.1016/j.ejps.2005.08.008. Epub 2005 Sep 23.
3
Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19.
Pharmacogenomics J. 2005;5(6):365-73. doi: 10.1038/sj.tpj.6500330.
4
Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester.
J Pharmacol Exp Ther. 2003 Sep;306(3):861-9. doi: 10.1124/jpet.103.052696. Epub 2003 Jun 12.
5
Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment.
Int J Cancer. 2003 Mar 1;103(6):810-4. doi: 10.1002/ijc.10896.
6
Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli.
Pharmacogenetics. 2002 Oct;12(7):543-53. doi: 10.1097/00008571-200210000-00006.
Zotero 插件